checkAd

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of a restricted stock unit (RSU) award for 1,260 shares of Syros common stock to one newly hired employee in connection with the employee’s commencement of employment with Syros. These RSUs were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs were granted on September 30, 2022 and vest as to one-quarter of the shares on September 30, 2023 and as to an additional one-quarter of the shares at the end of each successive year thereafter, subject to the employee’s continued service with Syros, and are subject to the terms and conditions of a restricted stock unit agreement covering the award and Syros’ 2022 Inducement Stock Incentive Plan.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.


The Syros Pharmaceuticals Stock currently trades with a raise of +11,60 % to 6,64EUR on the Tradegate stock exchange.



0 Kommentare
Nachrichtenquelle: Business Wire (engl.)
 |  110   |   |   

Schreibe Deinen Kommentar

Disclaimer

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of a restricted stock unit (RSU) award for 1,260 shares of Syros common stock to one newly hired employee …

Nachrichten des Autors

397 Leser
179 Leser
143 Leser
140 Leser
114 Leser
113 Leser
113 Leser
112 Leser
108 Leser
107 Leser
415 Leser
397 Leser
235 Leser
209 Leser
209 Leser
182 Leser
180 Leser
179 Leser
166 Leser
147 Leser
1142 Leser
766 Leser
589 Leser
515 Leser
501 Leser
492 Leser
472 Leser
464 Leser
464 Leser
434 Leser
7528 Leser
2918 Leser
2431 Leser
2402 Leser
2158 Leser
2102 Leser
1787 Leser
1699 Leser
1586 Leser
1533 Leser